The Role of Chemotherapy Rechallenge in in EGFR-Mutant NSCLC

Heather Wakelee, MD, and Helena Yu, MD, evaluate the clinical role of chemotherapy rechallenge in the treatment landscape. They discuss which patients may derive meaningful benefit, including those with a durable initial response, and how treatment-free interval factors into decision-making. The conversation also compares rechallenge strategies with alternative options such as antibody-drug conjugates and clinical trials, and whether chemotherapy rechallenge is underutilized or appropriately reserved.